A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

• Status: RECRUITING
• Trial end date: 2034-03-01

Summary

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.

The primary objectives of this study are as follows:

• To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
• To evaluate the safety of the study drug(s) in participants with HIV-1.

• Phase: PHASE4

Details

• Lead Sponsor: Gilead Sciences
• Treatments: bictegravir, emtricitabine, tenofovir alafenamide, drug combination; Cobicistat; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; emtricitabine tenofovir alafenamide; Ritonavir; Tablets